| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:SEC inhibitor KL-1
CAS:900308-84-1
Purity:98% Package:50mg Remarks:S57041
|
SEC inhibitor KL-1 manufacturers
- SEC inhibitor KL-1
-
- $34.00 / 1mg
-
2025-12-05
- CAS:900308-84-1
- Min. Order:
- Purity: 97.42%
- Supply Ability: 10g
|
| | SEC inhibitor KL-1 Basic information |
| Product Name: | SEC inhibitor KL-1 | | Synonyms: | SEC inhibitor KL-1;KL1;KL-1;KL 1;SEC inhibitor KL 1,KL 1,Inhibitor,SEC inhibitor KL-1,inhibit,KL1,SEC inhibitor KL1;2-Butenamide, N-(5-chloro-2-methylphenyl)-2-hydroxy-4-(3-methoxyphenyl)-4-oxo-;N-(5-Chloro-2-methylphenyl)-2-hydroxy-4-(3-methoxyphenyl)-4-oxobut-2-enamide;SEC inhibitor KL-1, 10 mM in DMSO;(2E)-N-(5-Chloro-2-methylphenyl)-2-hydroxy-4-(3-methoxyphenyl)-4-oxobut-2-enamide | | CAS: | 900308-84-1 | | MF: | C18H16ClNO4 | | MW: | 345.78 | | EINECS: | | | Product Categories: | | | Mol File: | 900308-84-1.mol |  |
| | SEC inhibitor KL-1 Chemical Properties |
| Boiling point | 552.4±50.0 °C(Predicted) | | density | 1.339±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 41.67 mg/mL (120.51 mM) | | pka | 8.09±0.50(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | SEC inhibitor KL-1 Usage And Synthesis |
| Uses | SEC inhibitor KL-1 (KL-1) is a peptide-like lead compound that is an effective selective SEC inhibitor. SEC inhibitor KL-1 promotes apoptosis and has anti-tumor activity. SEC inhibitor KL-1 doses dependently inhibits the AFF4-CCNT1 interaction, with a Ki value of 3.48 μM[1][2]. | | in vivo | SEC inhibitor KL-1 (50 mg/kg, administered intraperitoneally, once daily, 15 days) disrupts SEC, which can slow down tumor progression and improve survival rates in MDA231-LM2 tumor mice[2]. | Animal Model: | Mouse MDA231-LM2 tumor model[2] | | Dosage: | 50 mg/kg, once a day, 15 days | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Reduced tumor volume and significantly extended survival time of recipient mice. |
| | References | [1] Hiroaki Katagi, et al. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma. Neuro Oncol. 2021 Aug 2;23(8):1348-1359. DOI:10.1093/neuonc/noab009
[2] Liang K, et al. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced CancerTherapy. Cell. 2018 Oct 18;175(3):766-779. DOI:10.1016/j.cell.2018.09.027 |
| | SEC inhibitor KL-1 Preparation Products And Raw materials |
|